Explore advanced Treatment for Myelodysplastic Syndrome at Liv Hospital. From growth factors and Azacitidine to life-saving stem cell transplants.
Send us all your questions or requests, and our expert team will assist you.
Treatment and Procedures
Receiving a diagnosis of Myelodysplastic Syndrome (MDS) is a pivotal moment, but it is also the beginning of a structured path toward management and recovery. In the past, treatment options were limited primarily to blood transfusions and supportive care. Today, the landscape has transformed. We now have targeted drug therapies that can slow disease progression and advanced stem cell transplantation techniques that offer a potential cure.
At Liv Hospital, our approach to treating MDS is personalized and dynamic. We do not believe in a “one size fits all” protocol. Instead, our multidisciplinary tumor board reviews your specific genetic profile, risk score (IPSS-R), and overall health to craft a strategy that balances aggressive disease control with your quality of life. Whether you require low-intensity maintenance therapy or a high-complexity allogeneic transplant, our internationally accredited Bone Marrow Transplant Unit is equipped to guide you through every step of the process.
The first step in defining your treatment plan is risk stratification. Because MDS ranges from mild anemia to aggressive “pre-leukemia,” the intensity of treatment must match the severity of the disease.
For many patients, especially those with lower-risk disease, the foundation of treatment is “Supportive Care.” This does not mean giving up on treatment; rather, it means using medical interventions to correct the consequences of bone marrow failure.
If your red blood cells or platelets are critically low, transfusions can provide immediate relief from fatigue and prevent bleeding. At Liv Hospital, all blood products are irradiated and filtered to prevent reactions and reduce the risk of sensitization.
Frequent red blood cell transfusions can lead to a dangerous buildup of iron in the body (iron overload), which can damage the heart and liver. We monitor your ferritin levels closely and use oral medications (iron chelators) to remove excess iron and protect your organs.
Instead of replacing cells via transfusion, we can stimulate your bone marrow to produce more of its own.
For patients with higher-risk disease or those who do not respond to supportive care, we utilize “disease-modifying” drugs. These agents attack the abnormal cells directly to slow their growth or kill them.
These are the backbone of modern MDS treatment. Drugs like Azacitidine (Vidaza) and Decitabine (Dacogen) work by “switching on” genes that stop cancer cells from growing (tumor suppressor genes).
For a specific subtype of MDS called del(5q), the drug Lenalidomide (Revlimid) is highly effective. It targets the genetic abnormality directly, often eliminating the need for transfusions completely in these patients.
In some cases, MDS behaves like an autoimmune disease (similar to Aplastic Anemia), where the patient’s own immune system attacks the marrow. In these “hypocellular” MDS cases, drugs like ATG (Antithymocyte Globulin) and Cyclosporine can calm the immune system and allow the marrow to recover.
Currently, the only curative treatment for Myelodysplastic Syndrome is an Allogeneic Stem Cell Transplant. This procedure involves destroying the diseased bone marrow with high-dose chemotherapy and replacing it with healthy stem cells from a donor.
Because MDS is common in older adults (over 60) who may not tolerate high-dose chemotherapy, we often use “Reduced-Intensity” or “Mini-Transplants.” This approach uses lower doses of chemotherapy to suppress the immune system enough for the donor cells to take hold, relying on the new immune system (Graft-versus-Leukemia effect) to fight the cancer.
Treatment for MDS, particularly transplantation, is intensive. Managing complications is just as important as the treatment itself.
Send us all your questions or requests, and our expert team will assist you.
Generally, no. While drugs like Azacitidine can induce remission and control the disease for years, they are not considered curative. The disease usually returns eventually. A stem cell transplant remains the only proven cure.
Success rates vary based on age, disease risk, and donor match. However, for fit patients who undergo transplant early in the disease course, long-term disease-free survival can reach 40-60%. Delaying transplant until the disease transforms into leukemia significantly lowers the success rate.
Hypomethylating agents (Azacitidine) are typically given indefinitely as long as they are working. Cycles are usually repeated every 28 days. It often takes 4-6 cycles (months) to see the maximum benefit.
It depends on the treatment. Standard drugs like Azacitidine and Lenalidomide usually do not cause significant hair loss. However, the conditioning chemotherapy used before a stem cell transplant will cause temporary hair loss.
Liv Hospital coordinates with international bone marrow registries (like NMDP). If a fully matched unrelated donor cannot be found, our specialists can evaluate family members for a haploidentical (half-match) transplant, ensuring almost everyone has a donor option.
Your Comparison List (you must select at least 2 packages)
